Glenmark’s novel monoclonal antibody GBR 830 to enter phase II clinical studies
GBR 830 targets activated T cells, which drives the pathology in most autoimmune diseases including rheumatoid arthritis, multiple…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.